11 March 2022
Ahead of the Annual General Meeting in Alligator Bioscience AB on May 5, 2022, the Nomination Committee announces its proposals regarding Chairman of the Board, Vice Chairman of the Board and other Board members.
The Nomination Committee proposes:
- that the Board shall consist of seven ordinary Board members,
- that Anders Ekblom, Hans-Peter Ostler, Graham Dixon, Eva Sjökvist Saers and Veronica Wallin are re-elected as Board members,
- that Staffan Encrantz and Denise Goode are elected as new Board members,
- that Anders Ekblom is re-elected as Chairman of the Board, and
- that Hans-Peter Ostler is re-elected as Vice Chairman of the Board.
Staffan Encrantz, born 1951, is the founder and president of Allegro Investment, Inc., a company based in Menlo Park, California, which manages a $750 million investment portfolio. He has actively led investments in and operation of a variety of companies for over 30 years and has led the growth and development of both early-stage companies and established businesses in a wide variety of fields. Additionally, Staffan has extensive experience in commercial real estate, primarily in Sweden and USA, and of the hedge fund industry as representing substantial investors in a number of hedge funds and as former Board member of MKM Longboat Multi Strategy Fund Ltd. as well as a Board member of Harbour Solutions Group Ltd.
Other ongoing assignments: Chairman of AnaMar AB, Sweden, a company engaged in the research and development of drugs for fibrosis, Koncentra Verkstads AB, Sweden, a contract manufacturing group, Nclear Inc., Atlanta GA, a company working with environmental clean-up, Oxymetal SAS, France a laser and plasma steel cutting business and Sight Sciences Inc., Menlo Park CA, an eye care company developing and selling devices for surgical treatment of glaucoma and dry eye. Board member of Harbour Solutions Ltd, London, England, a dispute funding and insurance business and GovX Inc. San Diego, CA an e-commerce company.
Education: Law degree (Summa Cum Laude) from Uppsala University, Sweden.
Shareholding in Alligator Bioscience AB: As manager of the Allegro Investment Fund, Staffan Encrantz represents 55,642,092 shares in Alligator.
Denise Goode, born 1958, brings a wealth of financial, commercial, and life science industry experience, both from her extensive career as a senior pharmaceutical executive and from board and advisory roles held in life sciences since 2008. She has a deep understanding of the pharmaceuticals sector, finance and fundraising, and is highly experienced in business development. Previously, she had a 20 year career with AstraZeneca Pharmaceuticals PLC where she held global senior leadership roles within both finance and commercial activities. Denise is a PwC alumnus.
Other ongoing assignments: CEO of QED Life Sciences Limited, a consultancy company advising and supporting the strategic direction of biotech companies and providing business mentoring to CEOs and senior leaders. Board member of Abliva AB (publ) where she is chair of the remuneration committee and a member of the audit committee. VP, Business Development at AnaMar AB. Certified COVID vaccinator for the UK National Health Service.
Education: Bachelor of Science (Honours) in zoology from the University of Manchester, UK. Fellow of the Institute of Chartered Accountants in England and Wales.
Shareholding in Alligator Bioscience AB: –
The Nomination Committee's other proposals and reasoned statement will be presented in connection with the announcement of the notice to the Annual General Meeting 2022.
The Nomination Committee for the 2022 Annual General Meeting consists of:
- Lars Bergkvist (Chairman), representing Jonas Sjögren,
- Jan Lundström, representing Allegro Investment Fund, L.P.,
- Hans-Peter Ostler, representing Lars Spånberg, and
- Anders Ekblom, Chairman of the Board.
This information was submitted for publication, through the agency of the contact person set out above, at 12:00 CET on March 11, 2022.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.
For more information, please visit alligatorbioscience.com.